Successful use of oral prostaglandin E1 derivative for maintaining ductus-dependent systemic circulation in a neonate with trisomy 18

Cardiol Young. 2019 Sep;29(9):1222-1224. doi: 10.1017/S1047951119001902. Epub 2019 Aug 22.

Abstract

A Japanese female infant with trisomy 18 was diagnosed with hypoplastic left heart syndrome variant. She was administered oral prostaglandin E1 every 6 hours through a feeding tube as an alternative drug for lipo-prostaglandin E1. Oral prostaglandin E1 was effective for maintenance of the ductus arteriosus and may serve as a palliative treatment approach.

Keywords: CHD; Chromosomal disorder; palliative treatment; patent ductus arteriosus.

Publication types

  • Case Reports

MeSH terms

  • Abnormalities, Multiple*
  • Administration, Oral
  • Alprostadil / administration & dosage*
  • Dose-Response Relationship, Drug
  • Ductus Arteriosus / diagnostic imaging*
  • Female
  • Humans
  • Hypoplastic Left Heart Syndrome / diagnosis
  • Hypoplastic Left Heart Syndrome / drug therapy*
  • Infant, Newborn
  • Trisomy 18 Syndrome / diagnosis*
  • Vasodilator Agents / administration & dosage

Substances

  • Vasodilator Agents
  • Alprostadil